Fibrocell Science

Krystal Biotech eyes phase 3 for rare skin disease gene therapy

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.

Amirah Al Idrus Jun 24, 2019 11:13am

Close-up of handshake between person in suit and person in business shirt

Fibrocell, Castle Creek ink rare disease gene therapy pacts

Apr 15, 2019 11:18am